Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series
- 1 December 2018
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 105, 88-102
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- Bristol-Myers Squibb
- Roche
- Bristol-Myers Squibb
- Pfizer
- Celgene
- Ventana
- Bristol-Myers Squibb
- Bristol-Myers Squibb
- Amgen
- Bristol-Myers Squibb
- Genentech
- Merck
- Regeneron
- Amgen
- Pfizer
- Tolmar
This publication has 36 references indexed in Scilit:
- Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumabAnnals of the Rheumatic Diseases, 2017
- Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM groupSeminars in Arthritis and Rheumatism, 2016
- The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanomaAnnals of Oncology, 2016
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paperAnnals of Oncology, 2015
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Pancreatitis Secondary to Anti–Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CTClinical Nuclear Medicine, 2015
- Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with IpilimumabCancer Immunology Research, 2015
- Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti–CTLA-4 Antibody TherapyAmerican Journal of Roentgenology, 2011
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009